Gemcitabine is routinely used to treat pancreatic cancer, but many patients still succumb to the disease. In this study, researchers want to evaluate the safety and effectiveness of combining an investigational drug called M402 with gemcitabine in patients with previously untreated metastatic pancreatic cancer.
M402 is a blood thinner. In this study, a modified form of M402 (which has less blood-thinning properties) is being used, and laboratory studies have shown that it has anticancer effects. The goal of the initial part of the study is to find the highest dose of M402 that can be given safely with gemcitabine in patients.
M402 is an injection that patients (or their caregivers) can give themselves at home. Gemcitabine is given intravenously (by vein) in the clinic.